Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians
Autore:
Kinzie, JL; Naylor, PH; Nathani, MG; Peleman, RR; Ehrinpreis, MN; Lybik, M; Turner, JR; Janisse, JJ; Massanari, M; Mutchnick, MG;
Indirizzi:
Wayne State Univ, Sch Med, Div Gastroenterol, Detroit, MI USA Wayne State Univ Detroit MI USA Med, Div Gastroenterol, Detroit, MI USA Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA Wayne State Univ Detroit MI USA 48201 Dept Pathol, Detroit, MI 48201 USA Wayne State Univ, Sch Med, Ctr Hlth Care Effectiveness, Detroit, MI USA Wayne State Univ Detroit MI USA Hlth Care Effectiveness, Detroit, MI USA John B Dingell VA Med Ctr, Detroit, MI USA John B Dingell VA Med Ctr Detroit MI USA ell VA Med Ctr, Detroit, MI USA
Titolo Testata:
JOURNAL OF VIRAL HEPATITIS
fascicolo: 4, volume: 8, anno: 2001,
pagine: 264 - 269
SICI:
1352-0504(200107)8:4<264:AAWG1T>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC HCV INFECTION; LONG-TERM RESPONSE; CONTROLLED TRIAL; VIRAL LOAD; VIRUS-RNA; THERAPY; PREDICTORS; RIBAVIRIN; EFFICACY; ALFA;
Keywords:
hepatitis C; interferon; race;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Naylor, PH Wayne State Univ, Harper Hosp, Sch Med, Div Gastroenterol, 2 Webber Brown,3939 John R, Detroit, MI 48201 USA Wayne State Univ 2 Webber Brown,3939 John R Detroit MI USA 48201
Citazione:
J.L. Kinzie et al., "African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians", J VIRAL HEP, 8(4), 2001, pp. 264-269

Abstract

African Americans as a group have a higher incidence of chronic hepatitis C (CHC) than Caucasians but are often under-represented in clinical trials used to define response rates to interferon therapy. The aim of this study was to compare African Americans with Caucasians with respect to end-of-treatment response to interferon. This retrospective study had 61 African Americans and 49 Caucasians with CHC. All patients were treated for at least 12weeks with interferon-alpha 2b (Intron A) thrice weekly. End-of-treatment response was defined as three consecutive nondetectable HCV RNA measurements at least 1 month apart. Sustained response was defined as a negative serum HCV RNA 6 months after end of treatment. Of the 110 patients, 19 achievedan end-of-treatment response (17%) but only four achieved a sustained response (4/110=4%). Of the patients achieving a sustained response, one was genotype 1 (male Caucasian), three were genotype 2/3 with four patients having no follow-up information. The end-of-treatment response was 7% for patients with genotype 1 and 71% for genotype non-1 (P < 0.005 for genotype non-1). The end-of-treatment response was significantly higher in Caucasians (14/49=31%) compared with African Americans (5/61=8%; P < 0.05). A lower response rate in African Americans with genotype 1 in contrast to Caucasians wasthe primary reason for the difference in end-of-treatment response (1/45=2% vs. 5/33=15%, P < 0.05). Hence, interferon treatment resulted in a poor sustained response rate in the group of patients representative of the urbanpopulations with the highest prevalence of hepatitis C. A genotype other than type 1 was the strongest predictor of end-of-treatment response in patients treated but over 86% of patients in this urban clinic were genotype 1. Caucasians were more likely to respond than African Americans, especially in patients with genotype 1.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 00:27:23